Dr. Ritesh A. Mathur, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 543
Licensed in Texas since 2006, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
TX license M3315 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- Houston Methodist Hospital Houston, TX
- Houston Methodist Sugarland Hospital Sugar Land, TX
- Memorial Hermann Sugar Land Hospital Sugar Land, TX
Medical groups
- Ritesh A. Mathur, MD, PA (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 543
- Services billed
- 2,832
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,890 | 353 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 510 | 63 |
| Established patient office or other outpatient visit, 30-39 minutes | 442 | 203 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 203 | 102 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 173 | 161 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 95 | 88 |
| Hemodialysis procedure with physician evaluation | 50 | 32 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 49 | 31 |
| New patient office or other outpatient visit, 45-59 minutes | 39 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 22 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Calcitriol Other prescribers in Sugar Land, TX | 200 |
| Nifedipine Er (nifedipine) Other prescribers in Sugar Land, TX | 94 |
| Furosemide Other prescribers in Sugar Land, TX | 91 |
| Metoprolol Tartrate Other prescribers in Sugar Land, TX | 59 |
| Sevelamer Carbonate Other prescribers in Sugar Land, TX | 57 |
| Allopurinol Other prescribers in Sugar Land, TX | 50 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Sugar Land, TX | 50 |
| Velphoro (sucroferric oxyhydroxide) | 45 |
| Losartan Potassium Other prescribers in Sugar Land, TX | 43 |
| Levofloxacin Other prescribers in Sugar Land, TX | 41 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 39 payments worth $937 in total to this clinician.
| Travere Therapeutics, Inc. | $207 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $112 |
| Scpharmaceuticals Inc. | $79.49 |
| Lilly USA, LLC | $79.15 |
| Bayer HealthCare Pharmaceuticals Inc. | $77.33 |
| Novartis Pharmaceuticals Corporation | $56.85 |
| Opko Pharmaceuticals, LLC | $55.82 |
| Amgen Inc. | $55.50 |
| Food and Beverage | $920 |
|---|---|
| Education | $16.89 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Apr 25, 2025 | Education Filspari · Kidney Disease · in-kind | $16.89 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $38,102 in research payments for these studies, mostly to the institutions running them.
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.